After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution ...

AnaptysBio has spun off its biopharma pipeline into First Tracks Biotherapeutics, shifting to a royalty-focused, virtual ...

Ripple just published a four-phase roadmap to make XRPL quantum-resistant by 2028, putting it ahead of Bitcoin and Ethereum ...

If all goes well with that mission, humans will touch down near the moon's south pole on Artemis 4, which is currently slated ...

For most of its history, developmental testing of artillery has been the core mission of U.S. Army Yuma Proving Ground ...

A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal ...

Your talk at Extech 1 is focused on the characterization of recycled polyolefines as future food contact materials. What is ...

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

Gilead Sciences and Arcus Biosciences’ domvanalimab, one of the last anti-TIGIT antibodies still standing, has failed another trial—leading Gilead to pull further away from their once wide-ranging | ...

The mRNA-based Covid vaccines helped blunt the impact of the pandemic but also sparked political backlash that has threatened ...

Visitors to this year's Hannover Messe can experience a sudden drop in temperature at first hand—all brought about by simply ...

While the safety was more manageable, questions remain about whether the combination would best antibody-drug conjugate ...